Healthcare headlines were driven by major regulatory settlements, strategic pivots, and clinical updates today. Abbott agreed to pay $385 million over its 2022 baby formula plant closure, while Cellectis shares plunged 43% after abandoning its clinical CAR-T pipeline for preclinical gene editing. Additionally, GE HealthCare is pursuing a $1 billion acquisition of Sofie Biosciences, and AstraZeneca suffered a late-stage trial failure for its new breast cancer drug.
01Company specific
Novo Nordisk Rebrands to 'Novo' and Announces Corporate Changes
Losing dominance in the injectable obesity market forces a reliance on oral formulations where manufacturing scalability and earlier commercial launch dictate the next phase of market share.
Novo Nordisk is shortening its everyday name to Novo and overhauling its corporate culture as it loses ground to Eli Lilly in the obesity drug market. The Danish drugmaker will retain Novo Nordisk A/S as its legal name while adopting the new brand alongside the slogan Lasting Health Starts Now. Shares of Novo have dropped about 15% this year and fallen nearly 20% over the past year following a peak in 2024. The company held a 38.8% in the obesity space in the second quarter compared to Lilly's 60.9%, according to data cited in a Lilly presentation. Novo also recently scrapped three trials on an experimental cardiovascular drug and faced pressure over its pipeline. The rebrand accompanies a flipped bull logo and a new set of operating principles termed The Novo Way, aimed at simplifying workflows and focusing on direct-to-consumer delivery. The oral version of Wegovy has surpassed 3 million prescriptions as of June following its launch.
Cellectis Pivots Strategy to In Vivo Gene Editing, Discontinues Allogeneic CAR-T Programs
Abandoning clinical allogeneic CAR-T for preclinical base and epigenetic editors trades immediate oncology pipeline value for lower delivery complexity to survive against competing bispecific antibodies.
Cellectis has discontinued all clinical-stage development of its allogeneic CAR-T treatments and shifted its focus to preclinical in vivo gene editing medicines for cardiovascular disease. The French biotech is scrapping its lead candidate, lasme-cel, for B-cell acute lymphoblastic leukemia, alongside eti-cel for non-Hodgkin lymphoma, after citing rapidly changing treatment protocols and increased competition from bispecific antibodies and other therapies. The pivot will redirect resources toward two preclinical candidates, including an APOC3-targeting base editor named HEAL-101 and a PCSK9-targeting epigenetic editor named HEAL-201. Investors punished the announcement, sending the company's shares down as much as 43% in morning trading to roughly $2 apiece. The restructuring is intended to extend Cellectis' cash runway into the second half of 2028, following a quarter that closed with $169 million in the bank.
Definium's LSD drug achieves second Phase 3 trial win in anxiety disorder
Demonstrating rapid onset alongside late-stage replication positioning DT120 as the commercial benchmark for psychedelic therapies trying to displace daily oral psychiatric drugs.
Definitive Therapeutics reported results from its third readout this year for DT120, an oral LSD candidate targeting anxiety disorder. In the 12-week trial, patients receiving a 100-microgram dose experienced a 9.8-point drop on the Hamilton Anxiety Rating Scale, compared to a 4.7-point drop for the placebo group. The resulting 5.1-point difference matches the observed in the company's first late-stage study and outpaces many traditional therapies. Patients showed symptom changes as early as the second day following administration, offering a speed advantage over conventional antidepressants that require weeks to take effect. Definium now prepares to seek the first regulatory approval for a psychedelic drug treating anxiety.
Hamilton Anxiety Rating Scale Drop (Points)
DT120 patients achieved a 9.8-point drop compared to 4.7 for placebo.
Employer Health Insurance Costs Projected to Rise Through 2027
Rising employer healthcare costs absorb a larger share of fixed total compensation budgets, directly capping cash wage growth and dampening consumer spending power.
Fortune.com reports that employer healthcare costs per employee will jump 8.2% in 2027, marking the steepest increase since 2003 and the fifth consecutive year of rising expenses, according to a Mercer survey of 1,800 U.S. employers. Over 165 million Americans rely on employer-sponsored healthcare, but private employers already pay an average of $3.48 per hour for health insurance out of $14.07 per hour spent on total benefits. Two-thirds of companies with 500 or more employees plan to raise premiums, translating into faster-growing paycheck deductions for workers who contributed an average of about $6,850 toward family coverage last year. Hospital consolidation, less government spending, expensive new cancer treatments, -enabled medical billing, and weight-loss drugs are driving the cost increases, with GLP-1 use alone accounting for one percentage point of the total growth. Because total compensation is fixed, higher healthcare outlays eat into money that could otherwise fund .
Abbott Agrees to Settlement Regarding US Baby Formula Plant Closure
Concentrating nationwide infant formula production in single massive facilities transforms localized quality control failures into systemic supply shocks and direct Department of Justice regulatory enforcement.
statnews.com reports that Abbott Laboratories will pay $385 million to resolve claims tied to an investigation of contamination at a baby formula factory in Sturgis, Michigan. The facility is the largest of its kind in the United States and its closure triggered nationwide supply shortages in 2022. The contamination problems and subsequent shutdown prompted a lawsuit by the Justice Department alongside a major recall of powdered infant formula. The recall swept up several prominent brands including Similac, retail inventory that was already strained by pandemic stockpiling and broader disruptions.
GE HealthCare in Talks to Acquire Sofie Biosciences for $1 Billion
Securing in-house production of short-lived radiopharmaceuticals eliminates supply-chain bottlenecks for molecular imaging equipment makers, shifting competition from hardware design to proprietary diagnostic tracer access.
GE HealthCare is in talks to acquire radiopharmaceutical developer Sofie Biosciences for $1 billion. The potential transaction would give the medical imaging manufacturer full ownership of Sofie, which is currently backed by firm Trilantic Partners and counts Jubilant Pharma among its stakeholders. Trilantic previously valued Sofie at $550 million when it acquired a nearly 26 percent stake in 2024. The would expand GE HealthCare's pharmaceutical diagnostics division, a segment that generated $2.9 billion in last year and supplies agents used in scans alongside its existing MRI, CT, and PET equipment. This follows GE HealthCare's $2.3 billion agreement in March to buy software provider Intelerad, marking its second major deal since its 2023 from General Electric. A formal announcement could arrive as soon as next week.
AstraZeneca's Etcamah disappoints in advanced breast cancer trial
Failing to expand Etcamah beyond its narrow mutation-specific approval eliminates the primary volume driver required to hit AstraZeneca's long-term corporate growth targets.
AstraZeneca revealed that its newly approved breast cancer pill Etcamah missed its primary goal in a late-stage trial. The drug, combined with standard medication, failed to significantly delay disease progression compared to standard care alone in patients with advanced ER-positive, HER2-negative breast cancer. AstraZeneca reported only a numerical improvement in progression-free survival that fell short of statistical significance. The setback deals a blow to the drug class of oral selective estrogen receptor degraders, following a similar trial failure by Roche's giredestrant earlier this year. Etcamah recently secured an accelerated approval for patients with ESR1 mutations, a clearance that underpinned executive projections of $5 billion in peak annual sales. Those projections form part of a broader corporate goal to reach $80 billion in yearly by 2030. AstraZeneca intends to release detailed data from the SERENA-4 trial in due course.
Heavy corporate restructuring and clinical trial setbacks contrast with aggressive dealmaking in medical imaging. Whether rising corporate healthcare costs and high-profile drug failures will dampen broader sector investment through 2027 remains the key open question.
This, every morning.
SuMarket writes Healthcare and Pharmaceutical Sector every morning, along with every other section of the market and the companies and topics you follow. Free to read.